Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Work In Process (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Work In Process for 9 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process fell 2.12% year-over-year to $26.6 million, compared with a TTM value of $26.6 million through Dec 2025, down 2.12%, and an annual FY2025 reading of $26.6 million, down 2.12% over the prior year.
  • Work In Process was $26.6 million for Q4 2025 at Heron Therapeutics, up from $26.3 million in the prior quarter.
  • Across five years, Work In Process topped out at $29.0 million in Q1 2025 and bottomed at $9.0 million in Q2 2023.
  • Average Work In Process over 5 years is $18.3 million, with a median of $17.2 million recorded in 2023.
  • The sharpest move saw Work In Process soared 205.75% in 2021, then crashed 55.18% in 2023.
  • Year by year, Work In Process stood at $20.9 million in 2021, then dropped by 1.01% to $20.7 million in 2022, then dropped by 29.79% to $14.6 million in 2023, then surged by 86.87% to $27.2 million in 2024, then decreased by 2.12% to $26.6 million in 2025.
  • Business Quant data shows Work In Process for HRTX at $26.6 million in Q4 2025, $26.3 million in Q3 2025, and $26.1 million in Q2 2025.